Last updated on February 2019

Study of Safety and Efficacy of LNP023 in Patients With Kidney Disease Caused by Inflammation


Brief description of study

Efficacy and safety of LNP023 in IgAN patients

Detailed Study Description

The purpose of this Phase IIa/IIb dose ranging study is to generate human data in the intended patient population with IgAN to establish clinical proof-of-concept and to evaluate dose responses to support dose selection for subsequent clinical development of LNP023 for IgAN and potentially other indications

Clinical Study Identifier: NCT03373461

Contact Investigators or Research Sites near you

Start Over

Novartis Investigative Site

Melbourne, Australia
1.71miles
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.